Cross Country Healthcare (CCRN) Earnings Analysis
Cross Country Healthcare (CCRN) has no confirmed upcoming earnings date. Last quarter (2026-05-07) it beat with EPS -0.03 USD vs -0.05 USD est (+40%). It has beaten estimates in 1/5 recent quarters (20%). Trailing P/E -4.34.
Last updated 2026-07-23 · Source: FMP fundamentals + earnings calendar (company filings); consensus from sell-side analyst grades
When does CCRN next report earnings?
No confirmed upcoming earnings date is currently scheduled for CCRN. This page updates as the calendar is published.
CCRN earnings history — beats and misses
| Quarter (report date) | EPS actual | EPS est. | Surprise | Result |
|---|---|---|---|---|
| 2026-05-07 | -0.03 USD | -0.05 USD | +40% | Beat |
| 2026-03-04 | -0.06 USD | 0.03 USD | -300% | Miss |
| 2025-11-12 | 0.03 USD | 0.04 USD | -25% | Miss |
| 2025-03-05 | 0.04 USD | 0.11 USD | -63.6% | Miss |
| 2024-07-31 | 0.1 USD | 0.14 USD | -28.6% | Miss |
Beat rate: 1/5 (20%) over reported quarters with consensus data.
CCRN valuation and analyst view
| Trailing P/E | -4.34 |
|---|---|
| Trailing EPS | -3.13403 USD |
| Price / book | 1.33 |
| Dividend yield | 0.00% |
| Market cap | 0.43B |
| Analyst consensus | Hold (2 buy / 12 hold / 0 sell) |
| Avg price target | 10.61 USD |
Related research pages
Frequently asked questions
When is Cross Country Healthcare (CCRN)'s next earnings date?
No confirmed upcoming earnings date is currently scheduled for CCRN. This page updates as the calendar is published.
Did CCRN beat earnings last quarter?
In its 2026-05-07 report, CCRN posted EPS of -0.03 USD versus a -0.05 USD estimate — a beat of 40%.
What is CCRN's earnings track record?
Over the last 5 reported quarters with consensus data, CCRN beat estimates 1 times (20%).
What is CCRN's current P/E ratio and EPS?
CCRN trades at a trailing P/E of -4.34 on trailing EPS of -3.134032411820782 USD.
What do analysts rate CCRN?
Analyst consensus is "Hold" across 14 ratings (0 strong buy, 2 buy, 12 hold, 0 sell, 0 strong sell). Average 12-month price target: 10.61 USD.